Myeloid-derived suppressor cell accumulation and function in patients with newly diagnosed glioblastoma
Open accessThe DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
To assess the accumulation of myeloid-derived suppressor cells (MDSCs) in the peripheral blood of patients with glioma and to define their heterogeneity and their immunosuppressive function. Peripheral blood mononuclear cells (PBMCs) from healthy control subjects and from patients with newly diagnosed glioma were stimulated with anti-CD3/anti-CD28 and T cells assessed for intracellular expression of interferon (IFN)-γ. Antibody staining of PBMCs from glioma patients and healthy donors (CD33, HLADR, CD15, and CD14) followed by 4-color flow cytometry analysis-defined MDSC levels in the peripheral blood. To assess the role of MDSCs in suppressing T cell IFNγ production, PBMCs were depleted of MDSCs using anti-CD33 and anti-CD15 antibody-coated beads prior to T cell stimulation. Enzyme-linked immunosorbent assays were used to assess plasma arginase activity and the level of granulocyte colony-stimulating factor (G-CSF). Patients with glioblastoma have increased MDSC counts (CD33+HLADR-) in their blood that are composed of neutrophilic (CD15(+); >60%), lineage-negative (CD15(-)CD14(-); 31%), and monocytic (CD14(+); 6%) subsets. After stimulation, T cells from patients with glioblastoma had suppressed IFN-γ production when compared with healthy, age-matched donor T cells. Removal of MDSCs from the PBMCs with anti-CD33/CD15-coated beads significantly restored T cell function. Significant increases in arginase activity and G-CSF levels were observed in plasma specimens obtained from patients with glioblastoma. The accumulation of MDSCs in peripheral blood in patients with glioma likely promotes T cell immune suppression that is observed in this patient population. Increased plasma levels of arginase and G-CSF may relate to MDSC suppressor function and MDSC expansion, respectively, in patients with glioma.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Myeloid-derived-suppressor cells as regulators of the immune system
Gabrilovich, D. I., & Nagaraj, S. (2009) · Nature Reviews Immunology · doi:10.1038/nri2506 · Cited by 6,753
Almand, B., Clark, J. I., Nikitina, E., van Beynen, J., English, N. R., Knight, S. C., Carbone, D. P., & Gabrilovich, D. I. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.1.678 · Cited by 1,337
Lieschke, G., Grail, D., Hodgson, G., Metcalf, D., Stanley, E., Cheers, C., Fowler, K., Basu, S., Zhan, Y., & Dunn, A. (1994) · Blood · doi:10.1182/blood.v84.6.1737.1737 · Cited by 962
Ko, J. S., Zea, A. H., Rini, B. I., Ireland, J. L., Elson, P., Cohen, P., Golshayan, A., Rayman, P. A., Wood, L., Garcia, J., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1332 · Cited by 862
Self-citationZea, A. H., Rodriguez, P. C., Atkins, M. B., Hernandez, C., Signoretti, S., Zabaleta, J., McDermott, D., Quiceno, D., Youmans, A., O'Neill, A., et al. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4505 · Cited by 851
Rodriguez, P. C., Ernstoff, M. S., Hernandez, C., Atkins, M., Zabaleta, J., Sierra, R., & Ochoa, A. C. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-1921 · Cited by 773
Serafini, P., Meckel, K., Kelso, M., Noonan, K., Califano, J., Koch, W., Dolcetti, L., Bronte, V., & Borrello, I. (2006) · The Journal of Experimental Medicine · doi:10.1084/jem.20061104 · Cited by 766
R EGULATION OF E NZYMES OF THE U REA C YCLE AND A RGININE M ETABOLISM
Morris, S. M. (2002) · Annual Review of Nutrition · doi:10.1146/annurev.nutr.22.110801.140547 · Cited by 725
Rodríguez, P. C., & Ochoa, A. C. (2008) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00608.x · Cited by 719
Arginase: an emerging key player in the mammalian immune system
Munder, M. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2009.00291.x · Cited by 694
Cited by
Coordinated regulation of myeloid cells by tumours
Gabrilovich, D. I., Ostrand-Rosenberg, S., & Bronte, V. (2012) · Nature Reviews Immunology · doi:10.1038/nri3175 · Cited by 3,544
Hiam-Galvez, K. J., Allen, B. M., & Spitzer, M. H. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-021-00347-z · Cited by 1,400
Lindau, D., Gielen, P., Kroesen, M., Wesseling, P., & Adema, G. J. (2013) · Immunology · doi:10.1111/imm.12036 · Cited by 815
Chang, A. L., Miska, J., Wainwright, D. A., Dey, M., Rivetta, C. V., Yu, D., Kanojia, D., Pituch, K. C., Qiao, J., Pytel, P., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-0144 · Cited by 640
(2013) · Advances in Cancer Research · doi:10.1016/b978-0-12-407190-2.00007-1 · Cited by 594
Wainwright, D. A., Chang, A. L., Dey, M., Balyasnikova, I. V., Kim, C. K., Tobias, A., Cheng, Y., Kim, J. W., Qiao, J., Zhang, L., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0514 · Cited by 576
Immune microenvironment of gliomas
Gieryng, A., Pszczolkowska, D., Walentynowicz, K. A., Rajan, W. D., & Kaminska, B. (2017) · Laboratory Investigation · doi:10.1038/labinvest.2017.19 · Cited by 538
Obermajer, N., Muthuswamy, R., Lesnock, J., Edwards, R. P., & Kalinski, P. (2011) · Blood · doi:10.1182/blood-2011-07-365825 · Cited by 497
Wainwright, D. A., Balyasnikova, I. V., Chang, A. L., Ahmed, A. U., Moon, K.-S., Auffinger, B., Tobias, A. L., Han, Y., & Lesniak, M. S. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2130 · Cited by 472
Glioblastoma-infiltrated innate immune cells resemble M0 macrophage phenotype
Gabrusiewicz, K., Rodriguez, B., Wei, J., Hashimoto, Y., Healy, L. M., Maiti, S. N., Thomas, G., Zhou, S., Wang, Q., Elakkad, A., et al. (2016) · JCI Insight · doi:10.1172/jci.insight.85841 · Cited by 445
Lin, H., Liu, C., Hu, A., Zhang, D., Yang, H., & Mao, Y. (2024) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01544-7 · Cited by 392
Myeloid‐derived suppressor cell heterogeneity in human cancers
Solito, S., Marigo, I., Pinton, L., Damuzzo, V., Mandruzzato, S., & Bronte, V. (2014) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.12469 · Cited by 386
Dumitru, C. A., Moses, K., Trellakis, S., Lang, S., & Brandau, S. (2012) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-012-1294-5 · Cited by 374
Molecular Heterogeneity and Immunosuppressive Microenvironment in Glioblastoma
DeCordova, S., Shastri, A., Tsolaki, A. G., Yasmin, H., Klein, L., Singh, S. K., & Kishore, U. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01402 · Cited by 346
Marini, O., Costa, S., Bevilacqua, D., Calzetti, F., Tamassia, N., Spina, C., De Sabata, D., Tinazzi, E., Lunardi, C., Scupoli, M. T., et al. (2017) · Blood · doi:10.1182/blood-2016-04-713206 · Cited by 341
Flores-Toro, J. A., Luo, D., Gopinath, A., Sarkisian, M. R., Campbell, J. J., Charo, I. F., Singh, R., Schall, T. J., Datta, M., Jain, R. K., et al. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1910856117 · Cited by 334
Myeloid-derived suppressor cell development is regulated by a STAT/IRF-8 axis
Waight, J. D., Netherby, C., Hensen, M. L., Miller, A., Hu, Q., Liu, S., Bogner, P. N., Farren, M. R., Lee, K. P., Liu, K., et al. (2013) · Journal of Clinical Investigation · doi:10.1172/jci68189 · Cited by 323
Human neutrophils: Their role in cancer and relation to myeloid-derived suppressor cells
Moses, K., & Brandau, S. (2016) · Seminars in Immunology · doi:10.1016/j.smim.2016.03.018 · Cited by 305
Tumor infiltrating immune cells in gliomas and meningiomas
Domingues, P., González-Tablas, M., Otero, Á., Pascual, D., Miranda, D., Ruiz, L., Sousa, P., Ciudad, J., Gonçalves, J. M., Lopes, M. C., et al. (2016) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2015.07.019 · Cited by 302
Temozolomide for immunomodulation in the treatment of glioblastoma
Karachi, A., Dastmalchi, F., Mitchell, D. A., & Rahman, M. (2018) · Neuro-Oncology · doi:10.1093/neuonc/noy072 · Cited by 300
Haist, M., Stege, H., Grabbe, S., & Bros, M. (2021) · Cancers · doi:10.3390/cancers13020210 · Cited by 295
“Despite conflicting reports about MDSC surface marker expression, the clinical value of MDSC has readily been demonstrated: Recent reports highlighted that the frequency of MDSC per se may reflect the tumor burden of cancer patients, thus showing a strong correlation between a high MDSC frequency and a poor prognosis…”
BackgroundGrabowski, M. M., Sankey, E. W., Ryan, K. J., Chongsathidkiet, P., Lorrey, S. J., Wilkinson, D. S., & Fecci, P. E. (2021) · Journal of Neuro-Oncology · doi:10.1007/s11060-020-03483-y · Cited by 270
Zhang, B., Wang, Z., Wu, L., Zhang, M., Li, W., Ding, J., Zhu, J., Wei, H., & Zhao, K. (2013) · PLoS ONE · doi:10.1371/journal.pone.0057114 · Cited by 269
Harnessing innate immune pathways for therapeutic advancement in cancer
Hu, A., Sun, L., Lin, H., Liao, Y., Yang, H., & Mao, Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01765-9 · Cited by 255
Sayour, E. J., McLendon, P., McLendon, R., De Leon, G., Reynolds, R., Kresak, J., Sampson, J. H., & Mitchell, D. A. (2015) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-014-1651-7 · Cited by 196
Mechanism and therapeutic potential of tumor-immune symbiosis in glioblastoma
Pang, L., Khan, F., Heimberger, A. B., & Chen, P. (2022) · Trends in Cancer · doi:10.1016/j.trecan.2022.04.010 · Cited by 67
“Although the biology of e-MDSCs is less clear in GBM, both M-MDSCs and PMN-MDSCs are increasedin the peripheral blood of patients with GBM. PMN-MDSCs show a higher frequency in GBM tumors, where they account for more than 60% of total tumor-in fi ltrating MDSCs [129].”
BackgroundImmunotherapy Resistance in Glioblastoma
Wang, E. J., Chen, J.-S., Jain, S., Morshed, R. A., Haddad, A. F., Gill, S., Beniwal, A. S., & Aghi, M. K. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2021.750675 · Cited by 34
Metadata
- Authors
- Raychaudhuri, B., Rayman, P., Ireland, J., Ko, J., Rini, B., Borden, E. C., Garcia, J., Vogelbaum, M. A., & Finke, J.
- Venue
- Neuro-Oncology
- Publisher
- Oxford University Press (OUP)
- Published
- 2011-06-01
- Volume
- 13
- Issue
- 6
- Pages
- 591-599
- ISSN
- 1522-8517 (ISSN-L)
- 1523-5866
- OpenAlex
- W2117728670
- Cited by
- 359
- References
- 32
- FWCI
- 9.57
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.